GBIM — GlobeImmune Share Price
Last trade - 00:00- $0.00m
- -$8.69m
- $6.46m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.77% | ||
| Return on Equity | -66.24% | ||
| Operating Margin | -33.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.11 | 14.64 | 22.52 | 5.97 | 6.46 | n/a | n/a | 9.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
Directors
- J. William Freytag CHM
- Timothy Rodell CEO (70)
- C. Jeffrey Dekker VFN (56)
- Augustine Lawlor IND (65)
- Daniel Mitchell IND (64)
- S. Edward Torres IND (58)
- Last Annual
- December 31st, 2015
- Last Interim
- March 31st, 2016
- Incorporated
- June 5th, 2002
- Public Since
- July 2nd, 2014
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 5,751,574
- Address
- 1450 Infinite Drive, LOUISVILLE, 80027
- Web
- https://globeimmune.com/
- Phone
- +1 7206672300
- Contact
- Susan Noonan
- Auditors
- EKS&H LLLP
Upcoming Events for GBIM
Similar to GBIM
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:09 UTC, shares in GlobeImmune are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in GlobeImmune last closed at $0.00 and the price had moved by -99.88% over the past 365 days. In terms of relative price strength the GlobeImmune share price has underperformed the S&P500 Index by -99.89% over the past year.
There is no consensus recommendation for this security.
GlobeImmune does not currently pay a dividend.
GlobeImmune does not currently pay a dividend.
GlobeImmune does not currently pay a dividend.
To buy shares in GlobeImmune you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in GlobeImmune had a market capitalisation of $0.00m.
Here are the trading details for GlobeImmune:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GBIM
Based on an overall assessment of its quality, value and momentum GlobeImmune is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GlobeImmune. Over the past six months, its share price has underperformed the S&P500 Index by -99.57%.
As of the last closing price of $0.00, shares in GlobeImmune were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The GlobeImmune PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
GlobeImmune's management team is headed by:
- J. William Freytag - CHM
- Timothy Rodell - CEO
- C. Jeffrey Dekker - VFN
- Augustine Lawlor - IND
- Daniel Mitchell - IND
- S. Edward Torres - IND